EDIT Editas Medicine Inc

🔔Mid Day Trading Update🔔 📅Monday 9/01/2023📅 🟢Bullish Activity🟢 $EXAS Gapping up this morning after the provider of cancer screening and diagnostic tests provided upbeat Q4 guidance earlier this morning. The company said that it expects Q4 revenue to come in a range of $550-552.7M above the $512.16M consensus and that it expects to achieve adjusted EBITDA profitability in Q4 and for all of 2023 rather than its prior target of Q3 2023. The January 20th 52.50 call being the highest volume contract. $BABA Also to the upside this morning after the Chinese internet giant received bullish support from both Goldman Sachs and Morgan Stanley. Goldman analyst Ronald Keung added Buy rated BABA to his firm’s “Conviction Buy List” and bumped his price target on the stock to $138.00 from $133.00, stating that the worst is behind them after two years of downward earnings revisions. Morgan Stanley analyst Gary Yu reiterated his Overweight rating and hiked his price target on the stock to $150